How do CheckMate 8HW results impact your sequencing of available therapies in dMMR/MSI-H metastatic colorectal cancer?

Will you now uniformly start with nivo/ipi > chemotherapy? If so, would you ever reintroduce another checkpoint monotherapy down the line? Or do you use checkpoint monotherapy and escalate to nivo/ipi at a subsequent line of treatment?

Community PollStarted

How do CheckMate 8HW results impact your treatment sequencing in dMMR/MSI-H metastatic colorectal cancer?

67 physicians have voted

Join Mednetto vote and see how they answered.

3 Answers

Mednet MemberInvited Expert

Medical Oncology · Stanford University Medical Center

Answered on

The results of CheckMate 8HW further reinforce the use of immunotherapy over chemotherapy for dMMR/MSI-H metastatic colorectal cancer. In 2025, in my practice, assuming a patient has no contraindications to immunotherapy, I see no role for chemotherapy in 1st line metastatic colorectal cancer that i...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert

Medical Oncology · University of Wisconsin

Answered on · Updated on

I am routinely assessing all stage IV colorectal cancer patients with dMMR/MSI-high disease for ipi/nivo, as I believe that is now the standard of care. However, when there is toxicity, I have a low threshold to drop the ipilimumab and continue with checkpoint inhibition if appropriate. I am also re...

Join for free or sign in to see the full answer

Mednet Member

Medical Oncology · University of Texas MD Anderson Cancer Center

Answered on · Updated on

In line with CheckMate 8HW, other critical studies, and NCCN guidelines, I treat all metastatic MSI-H colorectal patients with immune checkpoint inhibitors in first line, unless there is a clear contraindication. In CheckMate 8HW, we see significant improvement in both PFS and OS, as well as lower r...

Join for free or sign in to see the full answer